275 related articles for article (PubMed ID: 34464029)
1. Upadacitinib pharmacokinetics and exposure-response analyses of efficacy and safety in psoriatic arthritis patients - Analyses of phase III clinical trials.
Muensterman E; Engelhardt B; Gopalakrishnan S; Anderson JK; Mohamed MF
Clin Transl Sci; 2022 Jan; 15(1):267-278. PubMed ID: 34464029
[TBL] [Abstract][Full Text] [Related]
2. Exposure-Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit-Risk Assessment in Rheumatoid Arthritis.
Nader A; Mohamed MF; Winzenborg I; Doelger E; Noertersheuser P; Pangan AL; Othman AA
Clin Pharmacol Ther; 2020 Apr; 107(4):994-1003. PubMed ID: 31610021
[TBL] [Abstract][Full Text] [Related]
3. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.
McInnes IB; Anderson JK; Magrey M; Merola JF; Liu Y; Kishimoto M; Jeka S; Pacheco-Tena C; Wang X; Chen L; Zueger P; Liu J; Pangan AL; Behrens F
N Engl J Med; 2021 Apr; 384(13):1227-1239. PubMed ID: 33789011
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
[TBL] [Abstract][Full Text] [Related]
5. Exposure-Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection.
Mohamed MF; Klünder B; Camp HS; Othman AA
Clin Pharmacol Ther; 2019 Dec; 106(6):1319-1327. PubMed ID: 31194885
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study.
Kameda H; Takeuchi T; Yamaoka K; Oribe M; Kawano M; Zhou Y; Othman AA; Pangan AL; Kitamura S; Meerwein S; Tanaka Y
Rheumatology (Oxford); 2020 Nov; 59(11):3303-3313. PubMed ID: 32277824
[TBL] [Abstract][Full Text] [Related]
7. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
Smolen JS; Pangan AL; Emery P; Rigby W; Tanaka Y; Vargas JI; Zhang Y; Damjanov N; Friedman A; Othman AA; Camp HS; Cohen S
Lancet; 2019 Jun; 393(10188):2303-2311. PubMed ID: 31130260
[TBL] [Abstract][Full Text] [Related]
8. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study.
McInnes IB; Kato K; Magrey M; Merola JF; Kishimoto M; Pacheco-Tena C; Haaland D; Chen L; Duan Y; Zueger P; Liu J; Lippe R; Pangan AL; Behrens F
RMD Open; 2021 Oct; 7(3):. PubMed ID: 34663636
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials.
Klünder B; Mittapalli RK; Mohamed MF; Friedel A; Noertersheuser P; Othman AA
Clin Pharmacokinet; 2019 Aug; 58(8):1045-1058. PubMed ID: 30945116
[TBL] [Abstract][Full Text] [Related]
10. Exposure-Response Analyses for Upadacitinib Efficacy and Safety in the Crohn's Disease CELEST Study and Bridging to the Extended-Release Formulation.
Mohamed MF; Klünder B; Lacerda AP; Othman AA
Clin Pharmacol Ther; 2020 Mar; 107(3):639-649. PubMed ID: 31594037
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
Burmester GR; Kremer JM; Van den Bosch F; Kivitz A; Bessette L; Li Y; Zhou Y; Othman AA; Pangan AL; Camp HS
Lancet; 2018 Jun; 391(10139):2503-2512. PubMed ID: 29908669
[TBL] [Abstract][Full Text] [Related]
12. Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study.
Mease PJ; Lertratanakul A; Papp KA; van den Bosch FE; Tsuji S; Dokoupilova E; Keiserman MW; Bu X; Chen L; McCaskill RM; Zueger P; McDearmon-Blondell EL; Pangan AL; Tillett W
Rheumatol Ther; 2021 Jun; 8(2):903-919. PubMed ID: 33913086
[TBL] [Abstract][Full Text] [Related]
13. Relative efficacy and safety of Janus kinase inhibitors for the treatment of active psoriatic arthritis: a network meta-analysis.
Lee YH; Song GG
Z Rheumatol; 2023 Jun; 82(5):408-416. PubMed ID: 34716775
[TBL] [Abstract][Full Text] [Related]
14. Use of upadacitinib in the treatment of psoriatic arthritis.
Ross Y; Magrey M
Immunotherapy; 2021 Dec; 13(18):1549-1554. PubMed ID: 34645316
[TBL] [Abstract][Full Text] [Related]
15. Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients.
Ponce-Bobadilla AV; Stodtmann S; Eckert D; Zhou W; Liu W; Mohamed MF
Clin Pharmacokinet; 2023 Jan; 62(1):101-112. PubMed ID: 36571701
[TBL] [Abstract][Full Text] [Related]
16. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2.
Mease PJ; Lertratanakul A; Anderson JK; Papp K; Van den Bosch F; Tsuji S; Dokoupilova E; Keiserman M; Wang X; Zhong S; McCaskill RM; Zueger P; Pangan AL; Tillett W
Ann Rheum Dis; 2021 Mar; 80(3):312-320. PubMed ID: 33272960
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies.
Baraliakos X; Ranza R; Östör A; Ciccia F; Coates LC; Rednic S; Walsh JA; Douglas K; Gao T; Kato K; Song IH; Ganz F; Deodhar A
Arthritis Res Ther; 2023 Apr; 25(1):56. PubMed ID: 37038159
[TBL] [Abstract][Full Text] [Related]
18. Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials.
Burmester GR; Winthrop K; Blanco R; Nash P; Goupille P; Azevedo VF; Salvarani C; Rubbert-Roth A; Lesser E; Lippe R; Lertratanakul A; Mccaskill RM; Liu J; Ruderman EM
Rheumatol Ther; 2022 Apr; 9(2):521-539. PubMed ID: 34970731
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study.
McInnes IB; Kato K; Magrey M; Merola JF; Kishimoto M; Haaland D; Chen L; Duan Y; Liu J; Lippe R; Wung P
Rheumatol Ther; 2023 Feb; 10(1):275-292. PubMed ID: 36243812
[TBL] [Abstract][Full Text] [Related]
20. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
Fleischmann R; Pangan AL; Song IH; Mysler E; Bessette L; Peterfy C; Durez P; Ostor AJ; Li Y; Zhou Y; Othman AA; Genovese MC
Arthritis Rheumatol; 2019 Nov; 71(11):1788-1800. PubMed ID: 31287230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
